Region

Country

Purchasing power parity exchange rate

Official exchange rate

Conversion factor

(1)

(2)

(3) = (1)*(2)

Afr-E

Kenya

17.10

0.013

0.22

Sear-D

India

8.65

0.022

0.19

MDG Target Group

Intervention (coverage)

Average yearly cost (millions $Int)

Average yearly DALYs averted (millions)

Average cost-effectiveness ratio (ACER)

Afr-E

Malaria

Case management with chloroquine-sulfadoxine-pyrimethamine combination treatment (95%)*

72

4.48

17

Malaria

Case management with sulfadoxine-pyrimethamine (95%)*

72

4.11

29

Malaria

Case management with chloroquine (95%)*

72

2.50

41

Under 5s

Complementary feeding (95%)**

3,334

0.08

42,680

Sear-D

Under 5s

Complementary feeding (95%)**

7,684

0.58

13,206

*Dominated by case management with artemisinin-based combination therapy.
**Dominated by improved complementary feeding, growth monitoring and promotion.

No.

Goal

Intervention (coverage)

Incremental yearly cost (millions $Int)

Incremental yearly DALYs averted (millions)

Incremental cost effectiveness ratio ($Int/DALY averted)

Highly cost-effective interventions*

A1

Maternal and neonatal health

Community-based case management for neonatal pneumonia (95%)

1

1.45

1

A2

HIV and AIDS

Mass media campaign to promote safer sex (100%)

16

4.54

3

A3

HIV and AIDS

Peer education and treatment of sexually transmitted infections for sex workers (50%)

42

11.07

4

A4

HIV and AIDS

Peer education and treatment of sexually transmitted infections for sex workers (expanded to 80%)

22

5.65

4

A5

HIV and AIDS

Peer education and treatment of sexually transmitted infections for sex workers (expanded to 95%)

10

2.56

4

A6

Tuberculosis

Treatment of new smear-positive TB cases only under DOTS (50%)

146

23.56

6

A7

Maternal and neonatal health

Community newborn package (95%):
Support for breastfeeding mothers
Support for low birth weight babies

57

7.10

8

A8

Tuberculosis

Treatment of new smear-positive TB cases only under DOTS (expanded to 80%)

116

14.14

8

A9

Malaria

Case management of malaria with artemisinin based combination treatment (95%)

73

5.89

12

A10

Tuberculosis

Treatment of new smear-positive tuberculosis cases only under DOTS (expanded to 95%)

104

7.07

15

A11

Under 5s

Vitamin A fortification of food staple (95%)
Zinc fortification of food staple (95%)

23

1.20

19

A12

Maternal and neonatal health

Tetanus toxoid (95%)

67

3.06

22

A13

HIV and AIDS

Prevention of mother-to-child transmission (ANC coverage)

82

3.47

27

A14

Maternal and neonatal health

Screening for pre-eclampsia (95%)
Screening & treatment of asymptomatic bacteruria (95%)
Screening & treatment of syphillis (95%)

35

1.28

29

A15

Under 5s

Measles vaccination (80%)

5

0.17

40

A16

Maternal and neonatal health

Normal delivery by skilled attendant (95%)
Active management of the third stage of labour (95%)
Initial management of post-partum haemorrhage (95%)
Neonatal resuscitation (95%)

124

3.06

42

A17

Maternal and neonatal health

Treatment of severe pre-eclampsia/eclampsia (95%)

22

0.53

46

A18

Malaria

Insecticide treated bed nets (95%)

182

3.25

56

A19

Under 5s

Measles vaccination (exapnded to 95%)

2

0.03

58

A20

Maternal and neonatal health

Facility-based care of very low birth weight babies, severe neonatal infections, severe neonatal asphyxia and neonatal jaundice (95%)

192

3.15

61

A21

HIV and AIDS

Treatment of sexually transmitted infections (current coverage)

41

0.60

68

A22

Under 5s

Case management for childhood pneumonia (80%)

170

2.34

73

A23

Maternal and neonatal health

Management of obstructed labour, breech and fetal distress (95%)

91

1.25

73

A24

HIV and AIDS

Treatment of sexually transmitted infections (expanded to ANC coverage)

67

0.84

80

A25

Under 5s

Vitamin A supplementation (80%, replaces fortification)
Zinc supplementation (80%, replaces fortification)

125

1.47

85

A26

Tuberculosis

Treatment of smear-negative tuberculosis cases under DOTS (95%)

246

2.60

94

A27

Under 5s

Oral rehydration therapy for diarrhoea (80%)

386

3.65

106

A28

Maternal and neonatal health

Antenatal steroids for pre-term births (95%)

117

1.00

117

A29

Malaria

Indoor residual spraying (95%)

186

1.58

118

A30

Tuberculosis

Treatment of multi-drug resistant tuberculosis under DOTS-Plus (95%)

127

1.03

123

A31

Maternal and neonatal health

Management of maternal sepsis (95%)

42

0.33

125

A32

Malaria

Intermittent presumptive treatment during pregnancy (95%)

1

0.01

151

A33

Maternal and neonatal health

Antibiotics for pre-term premature rupture of membranes (95%)

34

0.19

178

A34

HIV and AIDS

Voluntary counseling and testing (95%)

385

1.75

220

A35

Maternal and neonatal health

Referral care for severe post-partum haemorrhage (95%)

19

0.09

223

A36

Under 5s

Vitamin A Supplementation (expanded to 95%)
Case management for childhood pneumonia (expanded to 95%)
Zinc supplementation (expanded to 95%)
Oral rehydration therapy for diarrhoea (expanded to 95%)

395

1.62

243

A37

HIV and AIDS

Treatment of sexually transmitted infections (expanded to 95%)

117

0.40

290

A38

HIV and AIDS

Antiretroviral therapy: no intensive monitoring, first-line drugs only (95%)

1,266

2.32

547

A39

HIV and AIDS

School-based education on safer sex (95%)

77

0.12

631

A40

HIV and AIDS

Antiretroviral therapy: intensive monitoring, first-line drugs only (95%)

148

0.13

1,144

Not cost-effective interventions†

A41

HIV and AIDS

Antiretroviral therapy: intensive monitoring, first- and second-line drugs (95%)

5,133

0.99

5,175

A42

Under 5s

Improved complementary feeding, growth monitoring and promotion (95%)

1,630

0.13

12,791

No.

Goal

Intervention (coverage)

Incremental yearly cost (millions $Int)

Incremental yearly DALYs averted (millions)

Incremental cost-effectiveness ratio ($Int/DALY averted)

Highly cost-effective interventions*

B1

HIV and AIDS

Peer education and treatment of sexually transmitted infections for sex workers (50%)

83

29.93

3

B2

HIV and AIDS

Peer education and treatment of sexually transmitted infections for sex workers (expanded to 80%)

39

12.12

3

B3

HIV and AIDS

Peer education and treatment of sexually transmitted infections for sex workers (expanded to 95%)

19

4.54

4

B4

Maternal and neonatal health

Community-based support for breastfeeding mothers (50%)

49

8.50

6

B5

Maternal and neonatal health

Community-based support for breastfeeding mothers (expanded to 80%)

31

5.10

6

B6

Tuberculosis

Treatment of new smear-positive tuberculosis cases only under DOTS (80%)

443

64.52

7

B7

Maternal and neonatal health

Community-based support for breastfeeding mothers (expanded to 95%)

18

2.55

7

B8

Maternal and neonatal health

Tetanus toxoid (80%)

57

7.48

8

B9

Tuberculosis

Treatment of new smear-positive tuberculosis cases only under DOTS (expanded to 95%)

94

12.10

8

B10

Maternal and neonatal health

Tetanus toxoid (expanded to 95%)

39

4.43

9

B11

Under 5s

Zinc fortification of food staple (95%)

12

0.90

14

B12

Maternal and neonatal health

Community-based support for low birth weight babies (95%)

1

0.06

20

B13

HIV and AIDS

Mass media campaign to promote safer sex (100%)

33

0.66

51

B14

Tuberculosis

Treatment of smear-negative tuberculosis cases under DOTS (95%)

347

6.73

52

B15

Under 5s

Vitamin A fortification of food staple (95%)

37

0.53

70

B16

Under 5s

Case management for childhood pneumonia (80%)

316

4.26

74

B17

Maternal and neonatal health

Normal delivery by skilled attendant (95%)
Active management of third stage & initial treatment of post-partum haemorrhage (95%)

231

2.62

88

B18

Under 5s

Case management for childhood pneumonia (expanded to 80%)

105

1.07

99

B19

Under 5s

Measles vaccination (95%)

14

0.14

102

B20

Maternal and neonatal health

Screening for pre-eclampsia (95%)
Screening & treatment of asymptomatic bacteruria (95%)

49

0.40

123

B21

HIV and AIDS

Treatment of sexually transmitted infections (95%)

336

2.53

133

B22

Maternal and neonatal health

Community-based case management for neonatal pneumonia (95%)

9

0.06

144

B23

Under 5s

Zinc supplementation (95%, replaces fortification)
Oral rehydration therapy for diarrhoea (95%)

951

6.00

158

B24

Maternal and neonatal health

Neonatal resucitation (95%)
Treatment of severe pre-eclampsia/eclampsia (95%)

52

0.24

218

B25

Tuberculosis

Treatment of multi-drug resistant tuberculosis under DOTS-Plus (95%)

389

1.72

226

B26

Maternal and neonatal health

Referral care for severe post-partum haemorrhage (95%)

34

0.13

261

B27

Maternal and neonatal health

Management of maternal sepsis (95%)

83

0.29

290

B28

HIV and AIDS

Voluntary counseling and testing (95%)

182

0.57

317

B29

Under 5s

Vitamin A supplementation (95%, replaces fortification)

534

1.53

350

B30

HIV and AIDS

Prevention of mother-to-child transmission (ANC coverage)

155

0.31

614

B31

Maternal and neonatal health

Facility-based care of very low birth weight babies, severe neonatal infections, severe neonatal asphyxia and neonatal jaundice (95%)

385

0.63

699

B32

HIV and AIDS

Screening & treatment of syphillis (95%)

9

0.01

760

B33

Maternal and neonatal health

Antiretroviral therapy: no intensive monitoring, first-line drugs only (95%)

456

0.60

850

B34

HIV and AIDS

Antiretroviral therapy: intensive monitoring, first-line drugs only (95%)

27

0.02

1,295

Cost-effective interventions†

B35

HIV and AIDS

School-based education (95%)

176

0.08

2,192

B36

Maternal and neonatal health

Management of obstructed labour, breech and fetal distress (95%)

186

0.07

2,638

B37

Maternal and neonatal health

Antibiotics for pre-term premature rupture of membranes (95%)

65

0.02

2,808

Not cost-effective interventions‡

B38

HIV and AIDS

Antiretroviral therapy: intensive monitoring, first- and second-line drugs (95%)

861

0.20

4,406

B39

Maternal and neonatal health

Antenatal steroids for pre-term births (95%)

319

0.02

16,930

B40

Under 5s

Improved complementary feeding, growth monitoring and promotion (95%)

4,452

0.10

44,384